Baker Avenue Asset Management LP Buys Shares of 429 Axon Enterprise, Inc. (NASDAQ:AXON)

Baker Avenue Asset Management LP bought a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 429 shares of the biotechnology company's stock, valued at approximately $255,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AXON. New Wave Wealth Advisors LLC bought a new position in shares of Axon Enterprise in the 4th quarter worth $40,000. Y.D. More Investments Ltd acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $45,000. Stonebridge Financial Group LLC bought a new stake in Axon Enterprise during the 4th quarter worth approximately $53,000. GPS Wealth Strategies Group LLC lifted its holdings in shares of Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in Axon Enterprise by 4,750.0% during the fourth quarter. Versant Capital Management Inc now owns 97 shares of the biotechnology company's stock worth $58,000 after buying an additional 95 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Stock Performance

AXON traded down $2.24 during trading hours on Friday, hitting $684.59. The stock had a trading volume of 642,401 shares, compared to its average volume of 764,683. Axon Enterprise, Inc. has a 1 year low of $273.52 and a 1 year high of $715.99. The company's fifty day simple moving average is $564.50 and its 200 day simple moving average is $583.86. The stock has a market cap of $53.29 billion, a PE ratio of 176.90, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.15 earnings per share. Equities analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the sale, the director now owns 1,627 shares of the company's stock, valued at approximately $899,275.44. This represents a 15.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. The trade was a 0.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Barclays upped their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. The Goldman Sachs Group increased their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Finally, Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Axon Enterprise presently has an average rating of "Moderate Buy" and an average target price of $640.91.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.